HBOT Conversations:
Dr. Hemal Mehta & Vibrant Health University
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
HBOT News Network welcomes back Dr. Hemal V. Mehta, M.D.; Medical Director of Vibrant Health of North Carolina. Dr. Mehta has joined HBOT News Network three times previously, where we focused heavily on the topics of fasting & regenerative medicine – see Dr. Mehta & Fasting, Dr. Mehta & Fasting (Part 2), and Dr. Mehta & Regenerative Medicine.
We are thrilled to have Dr. Mehta return to discuss Vibrant Health University. Vibrant Health University is a new start-up educational program through Vibrant Health. It is a way to help educate, not just the public, but also providers who are interested in performing regenerative therapies, regenerative injections, and providing an alternative to patients that’s not typically available.
Vibrant Health University wants to steer the medical field and general public away from the traditional heavy focus of pharmacology and surgical techniques; and educate people more on the integrative approaches available for regenerative therapies and regenerative treatments. What people can expect from Vibrant Health University (once it gets up and going), is a variety of online programs and podcasts they can watch. Then, if interested further, physicians can choose the option for an in-person educational program where Dr. Mehta or his team can visit the physician’s office (or the physician can visit them) and the physician can then witness live demonstrations, and learn how to do proper procedures for regenerative treatments, while incorporating their protocols into their treatment plans.
The courses at Vibrant Health University will be a structured program with a certification process. Dr. Mehta explains that they are planning to provide different tiers. For example, a lower tier, a medium tier, and a higher tier of education to providers based on their level of expertise, and based on how much knowledge they already have and how much they want to obtain. The ultimate goal of the program is to have the courses accredited by the appropriate certifying boards to count as continuing medical education for physicians.
Dr. Mehta & di Giralomo spend time discussing the importance of physician education, the continued benefits of fasting, and how to gain control of excessive inflammation.
Dr. Mehta remind us of Vibrant Health’s focus — to integrate traditional and non-traditional medicine to give each patient the best outlook and care. Ultimately, integrative medicine is integrating functional medicine and holistic therapies with what we’ve learned through history regarding how the human body works. God gave us everything we need to survive from the beginning of human life. Dr. Mehta ends this segment by explaining through the study of medicine, it’s incredibly difficult to not believe that there is a God or a higher power that has created this body. The human body is made to be able to tolerate all kinds of different injuries, in all kinds of different aspects of life, while adapting to the environment. There is absolutely no other machine that man has ever made that’s even similar to the divine healing capabilities of the human body.
If you’d like to know more about Vibrant Health University, please contact Vibrant Health at www.vibranthcs.com/contact/
Guest
Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Healing under pressure: Inside a military hyperbaric chamber
At 16, she had a stroke. At 17, her town burned in the Camp Fire. Now, as her community rebuilds, she's healing thanks to hyperbaric therapy. SACRAMENTO, Calif — February 2, 2017, started off as an ordinary day for the Pipkin Family. Patrick and Stacey Pipkin just...
Clinical Trial – High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC),
which may evolve to acute chest syndrome (ACS), the most common cause of death among adult
patients with SCD. Currently, there is no safe and effective treatment to abort VOC or
prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including
hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a
very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among
factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one
of the most potent and readily alterable. Current guidelines recommend oxygen therapy in
patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal
oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients
at risk of secondary ACS because they may experience acute desaturation. In contrast, various
case series suggest a potential beneficial role of intensified oxygen therapy targeting
hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the
latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at
high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to
100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60
L/min (which generates positive airway pressure and dead space flushing, that may prevent
evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In
patients with acute respiratory failure, HFNO has been shown to improve patient's comfort,
oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of
VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage
(MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and
Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in
hospital wards.
Clinical Trial – Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot
Cancer Institute)will be enrolled in the study. Patients will receive Melphalan on day -2 and
HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is
documented, the patients will be seen in clinic at least weekly through day +100.